Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

被引:29
|
作者
McCaughan, Georgia J. B. [3 ]
Fulham, Michael J. [1 ,3 ]
Mahar, Annabelle [3 ]
Soper, Judy [3 ,4 ]
Hong, Angela M. [1 ,2 ]
Stalley, Paul D. [3 ]
Tattersall, Martin H. N. [1 ,2 ]
Bhadri, Vivek A. [1 ,2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[2] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia
[4] Specialist Magnet Resonance Imaging, Newton, NSW, Australia
来源
关键词
Ewing sarcoma; Immunotherapy; Anti-programmed cell death-1 antibody; Case report; GENOMIC INSTABILITY; CANCER; SURVIVAL; EXPERIENCE; NIVOLUMAB; ANTIBODY; THERAPY; REPAIR; FAMILY; TUMORS;
D O I
10.1186/s13045-016-0278-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
    Georgia J. B. McCaughan
    Michael J. Fulham
    Annabelle Mahar
    Judy Soper
    Angela M. Hong
    Paul D. Stalley
    Martin H. N. Tattersall
    Vivek A. Bhadri
    Journal of Hematology & Oncology, 9
  • [2] Preclinical model to counter antidrug antibodies to programmed cell death-1 blockade
    Develasco, Marco A.
    Kura, Yurie
    Fujita, Kazutoshi
    Nishimoto, Mituhisa
    Sakai, Kazuko
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Hammond, Scott A.
    Dovedi, Simon J.
    Davies, Barry R.
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER SCIENCE, 2024, 115 : 1019 - 1019
  • [3] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [4] Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Expression Patterns in Ewing and Ewing-Like Sarcoma
    Tamura, A.
    Yoshida, M.
    Yamamoto, N.
    Nakamura, S.
    Fujiwara, T.
    Tahara, T.
    Saito, A.
    Kozaki, A.
    Kishimoto, K.
    Ishida, T.
    Hasegawa, D.
    Kosaka, Y.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S336 - S336
  • [5] Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies
    Zou, Yixin
    Yaguchi, Tomonori
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (03) : 264 - 275
  • [6] Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
    Niedzwiedzka-Rystwej, Paulina
    Majchrzak, Adam
    Aksak-Was, Bogusz
    Serwin, Karol
    Czajkowski, Zenon
    Grywalska, Ewelina
    Korona-Glowniak, Izabela
    Rolinski, Jacek
    Parczewski, Milosz
    CELLS, 2022, 11 (12)
  • [7] Programmed death-1 checkpoint blockade in acute myeloid leukemia
    Sehgal, Alison
    Whiteside, Theresa L.
    Boyiadzis, Michael
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1191 - 1203
  • [8] Programmed death-1 blockade for multiple basal cell carcinomas: clearing the field systemically?
    Haug, V.
    Schilling, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (03) : 566 - 567
  • [9] Programmed cell death-1 inhibition in lymphoma
    Hawkes, Eliza A.
    Grigg, Andrew
    Chong, Geoff
    LANCET ONCOLOGY, 2015, 16 (05): : E234 - E245
  • [10] Tumor Progression by Immune Evasion in Melanoma Role of the Programmed Cell Death-1/Programmed Cell Death-1 Ligand 1 Interaction
    Kashani-Sabet, Mohammed
    CANCER, 2010, 116 (07) : 1623 - 1625